{"id":66688,"date":"2026-05-29T14:25:02","date_gmt":"2026-05-29T06:25:02","guid":{"rendered":"https:\/\/flcube.com\/?p=66688"},"modified":"2026-05-29T14:25:03","modified_gmt":"2026-05-29T06:25:03","slug":"yoltech-therapeutics-secures-500m-series-c-financing-to-advance-in-vivo-gene-editing-pipeline-including-chinas-first-lnp-based-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66688","title":{"rendered":"YolTech Therapeutics Secures $500M Series C Financing to Advance In Vivo Gene-Editing Pipeline Including China&#8217;s First LNP-Based Therapy"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>YolTech Therapeutics<\/strong>, a China-based biotechnology company founded in 2021, announced the completion of a <strong>$500 million Series C financing round<\/strong> (approximately <strong>$74 million<\/strong>), led by <strong>Loyal Valley Capital<\/strong>. The company is pioneering <strong>in vivo gene-editing medicines<\/strong> with the potential to deliver &#8220;<strong>one dose, lifelong cure<\/strong>&#8221; for genetic disorders.<\/p>\n\n\n\n<h2 id=\"h-financing-details\" class=\"wp-block-heading\">Financing Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Round<\/strong><\/td><td>Series C<\/td><\/tr><tr><td><strong>Amount<\/strong><\/td><td>$500 million ($74 million)<\/td><\/tr><tr><td><strong>Lead Investor<\/strong><\/td><td>Loyal Valley Capital<\/td><\/tr><tr><td><strong>Company Founded<\/strong><\/td><td>2021<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>In vivo gene-editing medicines<\/td><\/tr><tr><td><strong>Investment Use<\/strong><\/td><td>Clinical advancement and platform development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-proprietary-technology-platforms\" class=\"wp-block-heading\">Proprietary Technology Platforms<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>High-Throughput Editor Mining &amp; Evolution Platform:<\/strong> Enables rapid discovery and optimization of novel gene-editing enzymes<\/li>\n\n\n\n<li><strong>Non-Viral LNP Delivery System:<\/strong> Capable of targeting multiple tissues and organs without viral vectors<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Combines cutting-edge editing capabilities with tissue-specific delivery, addressing key challenges in gene therapy<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-pipeline-progress\" class=\"wp-block-heading\">Clinical Pipeline Progress<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Indication<\/th><th>Development Stage<\/th><th>Key Milestone<\/th><\/tr><\/thead><tbody><tr><td><strong>YOLT-201<\/strong><\/td><td>ATTR amyloidosis<\/td><td>Phase I\/IIa completed<\/td><td><strong>China&#8217;s first LNP-based in vivo gene-editing drug<\/strong> in registered clinical trials; all patients dosed<\/td><\/tr><tr><td><strong>YOLT-203<\/strong><\/td><td>Primary hyperoxaluria<\/td><td>Confirmatory trials<\/td><td>Entered U.S. confirmatory clinical trials in 2025<\/td><\/tr><tr><td><strong>Additional Programs<\/strong><\/td><td>Hypercholesterolemia, alpha-1 antitrypsin deficiency, other life-threatening diseases<\/td><td>Clinical development<\/td><td>Multiple assets advanced to clinical stages<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The company currently has <strong>six pipeline assets<\/strong> in clinical development, demonstrating rapid progression since its 2021 founding.<\/p>\n\n\n\n<h2 id=\"h-strategic-market-position\" class=\"wp-block-heading\">Strategic Market Position<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Gene Therapy Leadership:<\/strong> YOLT-201 represents a significant milestone as China&#8217;s first LNP-based in vivo gene-editing therapy to reach registered clinical trials<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> U.S. clinical presence through YOLT-203 establishes international footprint<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Diverse pipeline across multiple therapeutic areas validates the versatility of YolTech&#8217;s proprietary platforms<\/li>\n\n\n\n<li><strong>Investment Confidence:<\/strong> Substantial Series C funding reflects strong investor confidence in both the technology platform and clinical progress<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-context\" class=\"wp-block-heading\">Competitive Landscape Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Technology<\/th><th>Delivery System<\/th><th>Lead Indication<\/th><th>China Presence<\/th><\/tr><\/thead><tbody><tr><td><strong>YolTech Therapeutics<\/strong><\/td><td>In vivo gene-editing<\/td><td><strong>Non-viral LNP<\/strong><\/td><td>ATTR amyloidosis<\/td><td><strong>Domestic leader<\/strong><\/td><\/tr><tr><td><strong>Intellia Therapeutics<\/strong><\/td><td>CRISPR\/Cas9<\/td><td>LNP<\/td><td>Transthyretin amyloidosis<\/td><td>Limited<\/td><\/tr><tr><td><strong>Verve Therapeutics<\/strong><\/td><td>Base editing<\/td><td>LNP<\/td><td>Hypercholesterolemia<\/td><td>None<\/td><\/tr><tr><td><strong>Beam Therapeutics<\/strong><\/td><td>Base editing<\/td><td>Various<\/td><td>Sickle cell disease<\/td><td>None<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financing, clinical development, and commercial potential. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics in the rapidly evolving gene-editing landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>YolTech Therapeutics, a China-based biotechnology company founded in 2021, announced the completion of a $500&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[20,66,1168],"class_list":["post-66688","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-finance","tag-gene-therapy","tag-yoltech-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>YolTech Therapeutics Secures $500M Series C Financing to Advance In Vivo Gene-Editing Pipeline Including China&#039;s First LNP-Based Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"YolTech Therapeutics, a China-based biotechnology company founded in 2021, announced the completion of a $500 million Series C financing round (approximately $74 million), led by Loyal Valley Capital. The company is pioneering in vivo gene-editing medicines with the potential to deliver &quot;one dose, lifelong cure&quot; for genetic disorders.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66688\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"YolTech Therapeutics Secures $500M Series C Financing to Advance In Vivo Gene-Editing Pipeline Including China&#039;s First LNP-Based Therapy\" \/>\n<meta property=\"og:description\" content=\"YolTech Therapeutics, a China-based biotechnology company founded in 2021, announced the completion of a $500 million Series C financing round (approximately $74 million), led by Loyal Valley Capital. The company is pioneering in vivo gene-editing medicines with the potential to deliver &quot;one dose, lifelong cure&quot; for genetic disorders.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66688\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T06:25:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-29T06:25:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66688#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66688\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"YolTech Therapeutics Secures $500M Series C Financing to Advance In Vivo Gene-Editing Pipeline Including China&#8217;s First LNP-Based Therapy\",\"datePublished\":\"2026-05-29T06:25:02+00:00\",\"dateModified\":\"2026-05-29T06:25:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66688\"},\"wordCount\":373,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finance\",\"Gene therapy\",\"YolTech Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66688#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66688\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66688\",\"name\":\"YolTech Therapeutics Secures $500M Series C Financing to Advance In Vivo Gene-Editing Pipeline Including China's First LNP-Based Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-29T06:25:02+00:00\",\"dateModified\":\"2026-05-29T06:25:03+00:00\",\"description\":\"YolTech Therapeutics, a China-based biotechnology company founded in 2021, announced the completion of a $500 million Series C financing round (approximately $74 million), led by Loyal Valley Capital. The company is pioneering in vivo gene-editing medicines with the potential to deliver \\\"one dose, lifelong cure\\\" for genetic disorders.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66688#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66688\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66688#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"YolTech Therapeutics Secures $500M Series C Financing to Advance In Vivo Gene-Editing Pipeline Including China&#8217;s First LNP-Based Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"YolTech Therapeutics Secures $500M Series C Financing to Advance In Vivo Gene-Editing Pipeline Including China's First LNP-Based Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"YolTech Therapeutics, a China-based biotechnology company founded in 2021, announced the completion of a $500 million Series C financing round (approximately $74 million), led by Loyal Valley Capital. The company is pioneering in vivo gene-editing medicines with the potential to deliver \"one dose, lifelong cure\" for genetic disorders.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66688","og_locale":"en_US","og_type":"article","og_title":"YolTech Therapeutics Secures $500M Series C Financing to Advance In Vivo Gene-Editing Pipeline Including China's First LNP-Based Therapy","og_description":"YolTech Therapeutics, a China-based biotechnology company founded in 2021, announced the completion of a $500 million Series C financing round (approximately $74 million), led by Loyal Valley Capital. The company is pioneering in vivo gene-editing medicines with the potential to deliver \"one dose, lifelong cure\" for genetic disorders.","og_url":"https:\/\/flcube.com\/?p=66688","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-29T06:25:02+00:00","article_modified_time":"2026-05-29T06:25:03+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66688#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66688"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"YolTech Therapeutics Secures $500M Series C Financing to Advance In Vivo Gene-Editing Pipeline Including China&#8217;s First LNP-Based Therapy","datePublished":"2026-05-29T06:25:02+00:00","dateModified":"2026-05-29T06:25:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66688"},"wordCount":373,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finance","Gene therapy","YolTech Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66688#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66688","url":"https:\/\/flcube.com\/?p=66688","name":"YolTech Therapeutics Secures $500M Series C Financing to Advance In Vivo Gene-Editing Pipeline Including China's First LNP-Based Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-29T06:25:02+00:00","dateModified":"2026-05-29T06:25:03+00:00","description":"YolTech Therapeutics, a China-based biotechnology company founded in 2021, announced the completion of a $500 million Series C financing round (approximately $74 million), led by Loyal Valley Capital. The company is pioneering in vivo gene-editing medicines with the potential to deliver \"one dose, lifelong cure\" for genetic disorders.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66688#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66688"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66688#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"YolTech Therapeutics Secures $500M Series C Financing to Advance In Vivo Gene-Editing Pipeline Including China&#8217;s First LNP-Based Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66688"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66688\/revisions"}],"predecessor-version":[{"id":66691,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66688\/revisions\/66691"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66688"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66688"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}